GlassScriptPhysician profile
Andrew W Celmer
NPI 1376571604
$1,528.60
in general payments reported to CMS, 2019-2025
26 companies · $51.62 in 2025
The $51.62 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $150 · 2021: $287 · 2022: $287 · 2023: $148 · 2024: $344 · 2025: $51.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $265.02 | 2019-2024 | Trudi Nav Cable |
| Inspire Medical Systems, INC. | $174.58 | 2021-2024 | Inspire |
| Stryker Corporation | $162.62 | 2019-2024 | Scopis Ent, Xpress Loprofile |
| Regeneron Healthcare Solutions, INC. | $118.00 | 2019-2022 | |
| Aerin Medical INC. | $116.71 | 2024 | |
| Novartis Pharmaceuticals Corporation | $67.17 | 2019 | |
| Olympus America INC. | $64.05 | 2019-2024 | Rhino-Laryngo Videoscope |
| Glaxosmithkline, LLC. | $58.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.80 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $52.82 | 2019-2020 | |
| Conmed Corporation | $51.62 | 2025 | Airseal |
| Xoran Technologies LLC | $46.78 | 2020-2021 | |
| Smith+Nephew, INC. | $35.88 | 2023 | Halo |
| Astrazeneca Pharmaceuticals LP | $29.69 | 2021 | |
| Alk-Abello, INC | $29.48 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2021 | |
| Advanced Bionics, LLC | $23.03 | 2019 | |
| Cochlear Americas | $21.91 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $20.32 | 2021 | |
| Tactile Systems Technology INC | $19.76 | 2020 | |
| Intersect Ent, INC. | $17.81 | 2019 | |
| Pfizer INC. | $16.75 | 2023 | |
| Hikma Pharmaceuticals USA | $15.48 | 2024 | Ryaltris |
| Kaleo, INC. | $15.23 | 2019 | |
| Endogastric Solutions, INC | $13.54 | 2023 | Esophyx |
| Jazz Pharmaceuticals INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Celmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.